SCPH SCPharmaceuticals Inc

scPharmaceuticals to Announce Second Quarter 2025 Financial Results After the Market Close on August 7, 2025

scPharmaceuticals to Announce Second Quarter 2025 Financial Results After the Market Close on August 7, 2025

Management to host conference call and webcast, after-market on August 7, 2025, at 4:30 p.m. ET

BURLINGTON, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Thursday, August 7, 2025, to discuss the financial results for the second quarter 2025 and provide a business update.

A link to the live webcast can be found .

Participants should dial (800) 715-9871 (toll-free) or (646) 307-1963 (toll) and use the passcode 4965353

The live webcast and replay of the conference call can be accessed or under “News & Events” in the Investor Relations section of the Company’s website, .

About scPharmaceuticals

At scPharmaceuticals, we are powered by passion, driven by patient care. Our Mission is focused on advancing cardiorenal care through innovative, integrated treatments that address unmet patient needs.

Our goal is to become the foremost advocate for patient-centric cardiorenal care, driving global health improvements through specialized, multidisciplinary approaches. scPharmaceuticals is expanding its reach, offering integrated therapies and products that address diverse healthcare needs and potentially improve the lives of our patients. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit .

Katherine Miranda

scPharmaceuticals Inc., (781) 301-6869

Investors:

Matthew Beck

astr partners, (917) 415-1750



EN
31/07/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SCPharmaceuticals Inc

 PRESS RELEASE

MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and...

MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX®, an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unmet needUpfront cash payment of $5.35 per share plus one non-tradable contingent value right (CVR) per share payable upon achieving specific regulatory and net sales milestones worth up to $1.00 per CVR in cash Upfront cash payment represents ...

 PRESS RELEASE

scPharmaceuticals Receives Notice of Allowances of Multiple US Patent ...

scPharmaceuticals Receives Notice of Allowances of Multiple US Patent Applications Covering SCP-111 BURLINGTON, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, announced today that it has received five Notices of Allowance from the United States Patent and Trademark Office (USPTO) for patent applications covering their latest furosemide formulation, SCP-111. The SCP-111 formulation is the subject of a supplemental NDA expected to...

 PRESS RELEASE

scPharmaceuticals Inc. Reports Second Quarter 2025 Financial Results a...

scPharmaceuticals Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update Generated net FUROSCIX® revenue of $16 million in the second quarter of 2025; up 99% over Q2 2024 Doses shipped to patients increased 45% over Q1 2025 and 117% over Q2 2024 Launch of FUROSCIX in chronic kidney disease Autoinjector remains on track for sNDA submission in Q3 2025; designed to reduce treatment time from five hours to less than ten seconds Cash and cash equivalents of $40.8 million as of June 30, 2025 Investor conference call and webcast today, Thursday, August 7th, at 4:30pm ...

 PRESS RELEASE

scPharmaceuticals to Announce Second Quarter 2025 Financial Results Af...

scPharmaceuticals to Announce Second Quarter 2025 Financial Results After the Market Close on August 7, 2025 Management to host conference call and webcast, after-market on August 7, 2025, at 4:30 p.m. ET BURLINGTON, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Thursday, August 7, 2025, to discuss the financial results for the ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch